Publicaciones en colaboración con investigadores/as de Hospital Universitario Marqués de Valdecilla (16)

2024

  1. Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.

    New England Journal of Medicine, Vol. 391, Núm. 11, pp. 1002-1014

  2. Characterization of Chronic Graft-versus-host Disease After Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide: A Study on Behalf of GETH-TC

    Transplantation, Vol. 108, Núm. 10, pp. 2134-2143

  3. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8

2023

  1. Correction: Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT (Journal of Hematology & Oncology, (2023), 16, 1, (58), 10.1186/s13045-023-01450-4)

    Journal of Hematology and Oncology

  2. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)

    Bone Marrow Transplantation

  3. Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT

    Journal of Hematology and Oncology, Vol. 16, Núm. 1

  4. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

    Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679

  5. Second haploidentical stem cell transplantation (HAPLO-SCT2) after relapse from a first HAPLO-SCT in acute leukaemia—a study on behalf of the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

    Bone Marrow Transplantation, Vol. 58, Núm. 8, pp. 907-915

2022

  1. Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups

    Frontiers in Immunology, Vol. 13

  2. CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S440-S441

  3. Post-Transplantation Cyclophosphamide After HLA Identical Compared to Haploidentical Donor Transplant in Acute Myeloid Leukemia: A Study on Behalf of GETH-TC

    Transplantation and Cellular Therapy, Vol. 28, Núm. 4, pp. 204.e1-204.e10

2020

  1. Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant recipients: Study protocol for the prospective multicentre OptimBioma study

    BMJ Open, Vol. 10, Núm. 7

  2. Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 4, pp. 651-658

2019

  1. Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders

    AIDS, Vol. 33, Núm. 9, pp. 1441-1447

2018

  1. Busulfan-based myeloablative conditioning regimens for haploidentical transplantation in high-risk acute leukemias and myelodysplastic syndromes

    European Journal of Haematology, Vol. 101, Núm. 3, pp. 332-339

2017

  1. Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML

    Bone Marrow Transplantation, Vol. 52, Núm. 8, pp. 1138-1143